Summary: A new study shows that brain serotonin activity, measured by a simple EEG-based test, can help predict which patients will develop sexual side effects from SSRI antidepressants. The Loudness Dependence of Auditory Evoked Potentials (LDAEP) test identified people with higher pre-treatment serotonin activity as significantly more likely to experience difficulty reaching orgasm while taking SSRIs.
If confirmed in larger studies, this non-invasive measure could allow clinicians to tailor antidepressant selection to reduce sexual side effects, improve adherence, and enhance patients’ quality of life.
Key Facts:
- Predictive brain marker: The LDAEP EEG test estimates central serotonin activity and may forecast SSRI-related sexual dysfunction before medication begins.
- High predictive accuracy: In this sample of depressed patients, researchers predicted orgasm difficulties with up to 87% accuracy.
- Clinical impact: Using LDAEP to guide antidepressant choice could reduce distressing sexual side effects such as delayed orgasm, decreased desire, and erectile problems.
Source: European College of Neuropharmacology
Researchers presented these findings at the ECNP congress in Amsterdam. The study addressed a common and clinically important issue: sexual dysfunction in depression and the additional sexual side effects often caused by SSRI medications. While SSRIs can improve mood and sometimes improve sexual function indirectly, they are also frequently associated with new or worse sexual problems. Until now, clinicians had no reliable way to predict which patients would develop these adverse effects.
The Copenhagen team recruited 90 people diagnosed with depression and measured brain serotonin activity using the LDAEP test. LDAEP is an EEG-based assessment performed while presenting sounds at different volumes through headphones; paradoxically, the test’s results reflect serotonin system activity in the brain (a lower LDAEP slope indicates higher central serotonin activity).
Participants then began an eight-week SSRI treatment course, during which the researchers monitored sexual function and reported side effects. By comparing baseline LDAEP results with subsequent sexual outcomes, the investigators determined that higher pre-treatment serotonin activity was associated with a greater risk of developing SSRI-induced sexual dysfunction, especially difficulty achieving orgasm.
Lead researcher Dr Kristian Jensen (Copenhagen University Hospital) commented on the main findings: “We discovered that people with higher serotonin activity before treatment started were much more likely to develop sexual side effects by the end of the 8-week antidepressant course, especially difficulty reaching orgasm.” He added that combining the LDAEP measure with clinical information about a patient’s baseline sexual problems allowed prediction of orgasm ability with 87% accuracy, and noted the need for larger samples—particularly more men—to estimate the test’s accuracy for erectile dysfunction.
Dr Jensen explained the practical promise of the technique: “Measuring serotonin activity via the LDAEP test at the start of the course of antidepressants allows us to predict the likelihood of later sexual problems due to the SSRI. If confirmed, our findings could enable a more precise approach to depression treatment, helping doctors select medications to minimise sexual side effects in those patients most likely to develop SSRI-related problems. This could help treatment adherence and overall quality of life.”
The investigators emphasize that the test appears to predict medication-induced sexual problems rather than sexual dysfunction in general. To refine and validate these results, a larger multicentre study of 600 patients is underway; it will also examine how serotonin measures interact with sex hormone levels to influence sexual function during depression and medication.
Professor Eric Ruhe (Radboudumc, Nijmegen), who was not involved in the study, praised the approach: “This is a very interesting study where the researchers innovatively use an easy-to-administer test to predict the chance of sexual dysfunction after the start of antidepressant. When replicated, this type of test might reliably help to know beforehand whether a patient will have sexual adverse effects or not.” He highlighted the clinical value of reassuring patients who fear sexual side effects and urged further development of tools to recommend alternative medications based on such biomarkers.
Study limitations noted by the authors include the relatively young and predominantly female sample (average age 27; 73% female). The work is currently under peer review, and larger studies are planned to confirm the findings and determine how broadly the test can be applied in routine clinical practice.
About the LDAEP test
Dr Jensen described the LDAEP as an elegant, non-invasive EEG procedure: “We play sounds at different volumes through headphones while measuring brain waves. It takes about 30 minutes and is non-invasive. It’s not generally available at the moment, but that may change if this test lives up to expectations.”
Key Questions Answered:
A: Higher pre-treatment central serotonin activity, as measured by LDAEP, predicted a greater risk of SSRI-related sexual side effects—most notably difficulty reaching orgasm.
A: If validated, the LDAEP test could allow clinicians to anticipate which patients are at higher risk of sexual adverse effects and choose antidepressants or treatment strategies that minimise those risks.
A: Larger, more diverse studies—including a 600-patient trial—are underway to confirm these results and to investigate how serotonin and sex hormones together influence sexual function during depression and pharmacological treatment.
About this neuropharmacology and sexual function research news
Author: Tom Parkhill
Source: European College of Neuropharmacology
Contact: Tom Parkhill – European College of Neuropharmacology
Image: The image is credited to Neuroscience News
Original Research: The findings will be presented at the 38th ECNP Congress